OZEM Roundhill GLP-1 & Weight Loss ETF Loading... : Bullish and Bearish Analyst Opinions

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
17:19
Aug 18
Andrew Dudum CEO, Hims & Hers CNBC
Branded GLP-1 prices compress toward $40
GLP-1 therapies can be manufactured and delivered profitably for $40-$50 per month; prices will fall from $150-$200 to $99, then $79, and likely $40-$50 by 2030 because competition from new entrants and semaglutide patent expiration will compress branded pricing.
OZEM 1ST
HIGH
19:04
Apr 21
Keith McCullough Founder & CEO, Hedgeye Risk Management
Short weight-loss/GLP-1 sector names (proxied by OZEM) as McCullough maintains an ongoing short.
Short weight-loss/GLP-1 sector names (proxied by OZEM) as McCullough maintains an ongoing short position in the space, implying continued bearish conviction on the category.
OZEM 1ST
MED

About OZEM Analyst Coverage

Buzzberg tracks OZEM (Roundhill GLP-1 & Weight Loss ETF) across 2 sources. 0 bullish vs 1 bearish calls from 2 analysts. Sentiment: mixed to bearish. 2 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Andrew Dudum, Keith McCullough.